BioAdvance News Portfolio News Venatorx Pharmaceuticals

Venatorx Pharmaceuticals Awarded BARDA Project BioShield Contract

By WebmasterOctober 3, 2022November 1st, 2024No Comments

Venatorx Pharmaceuticals Awarded BARDA Project BioShield Contract

Total award of up to $318M for development and procurement of novel antibiotic cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections

See more here

Previous PostAnnovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease
Next PostRelmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder

Venatorx Pharmaceuticals Awarded BARDA Project BioShield Contract

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostAnnovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease

Next PostRelmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder